Navigation Links
LCS Constructors, Inc. Completes First Major Phase of Abraxis BioScience Project
Date:4/29/2010

IRVINE, Calif., April 29 /PRNewswire/ -- Abraxis BioScience initially engaged LCS Constructors, Inc. to perform an evaluation of the former ICN/Valient Pharmaceutical building in Costa Mesa, California prior to their purchasing this 165,000 square foot building. The "due diligence report" revealed an array of issues that required repair or retro-fit prior to occupying the building, and once the building purchase was complete, Abraxis called upon LCS to serve as Design-Builder for a multi-phase renovation.

With Senior Project Manager David P. Carlos leading the way and Superintendent Jim Koons heading up daily production, LCS recently completed significant seismic upgrades as well as restoring and renovating existing laboratory space to Abraxis' specifications. LCS was charged with ensuring that the end result would be a new "state-of-the-art" laboratory which includes labs for chemistry, biology, formulation, and a Biological Safety Lab 3 (BSL3).

The biggest challenges throughout the project were, literally, the seismic upgrades. Working on the second floor, the size and weight alone of the dampeners was too much to just place them anywhere. With each dampener between 15' and 19' long and weighing between 700 lbs and 1000 lbs each, they were just too large to install without significant planning.

The team strategized to figure out the best location for the dampeners which was both close to the work but out of the way, keeping both production and safety in mind. Because the seismic dampeners were not standard equipment, the installation presented other unique challenges in terms of tolerances. Additionally, in order to accurately plan for the installation of the dampeners, seismic models were created. These seismic models were a key element for understanding the purpose and the workings for this project.

"This has been a fantastic client and job to work on," stated Koons. And, although the team faced several unique challenges that accompanied these seismic upgrades, they were resourceful and that, combined with patience, planning and strategy, led to the successful completion of the first major phase of this project.

The relocation of Abraxis' research and development group from Marina Del Rey to Costa Mesa will provide the company more space to grow their operations. LCS was proud to renovate the new facility which will provide the technology necessary to propel Abraxis closer to their goals of finding new treatments for cancer and other pathological disorders.


'/>"/>
SOURCE LCS Constructors, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy ... announced that it has named Leah Bailey ... all divisions of the company. With more ... the previous 8 years focused on health care, Bailey ... her tenure at Prime, Bailey advised the PBM, Specialty, ...
(Date:3/29/2017)... Varian Medical Systems (NYSE: VAR ) ... quarter of fiscal year 2017 following the close of regular ... be followed by a teleconference available to all interested parties ... to the conference call webcast will be available on the ... call and replay: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical cannabis ... the company’s executive management team with prominent executives from both inside and outside the ... Operating Officer, Ted Dumbauld , who has more than twenty years of business ...
(Date:3/29/2017)... ... ... Hamlin Dental Group, multi-location dental office in North Hollywood , Van ... safe and effective options, and can be used alone or in conjunction with other ... care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as well, ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 million ... only option for on-premises installation of its Help System for SharePoint was at the ... system into the entire tenant. , The company recently released a modified version ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have ... World Travel Trends Report). As travelers visit both urban destinations, they are faced ... prolonged sun exposure. In response, the outdoor industry has blurred the lines between ...
Breaking Medicine News(10 mins):